

Catherine Sm Diefenbach

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7715344/catherine-sm-diefenbach-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

435
citations

9
h-index

20
g-index

42
ext. papers

681
ext. citations

5.8
avg, IF

3.23
L-index

#	Paper	IF	Citations
38	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. <i>Clinical Cancer Research</i> , 2016 , 22, 34-43	12.9	127
37	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019 , 6, e254-e265	14.6	108
36	Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. <i>Blood</i> , 2016 , 128, 622-622	2.2	20
35	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021 , 137, 374-386	2.2	19
34	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100931	2.2	15
33	New strategies in Hodgkin lymphoma: better risk profiling and novel treatments. <i>Clinical Cancer Research</i> , 2013 , 19, 2797-803	12.9	14
32	Relapsed Hodgkin lymphoma: management strategies. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 284-93	4.4	12
31	Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies. <i>Blood</i> , 2016 , 128, 5108-5108	2.2	12
30	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020 , 191, 44-51	4.5	10
29	Immune targeting of the microenvironment in classical Hodgkin lymphoma: insights for the hematologist. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719846451	5.7	9
28	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020 , 25, 878-885	5.7	9
27	Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients 2021 ,		9
26	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021 , 106, 1932-1942	6.6	8
25	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study. <i>Blood</i> , 2018 , 132, 2969-2969	2.2	7
24	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018 , 132, 1626-1626	2.2	7
23	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019 , 134, 402-402	2.2	7
22	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7

21	Laboratory Workup of Lymphoma in Adults. <i>American Journal of Clinical Pathology</i> , 2021 , 155, 12-37	1.9	5
20	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021 , 5, 2852-2862	7.8	5
19	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020 , 25, e993-e997	5.7	5
18	Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation. <i>Blood</i> , 2018 , 132, 5216-5216	2.2	3
17	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019 , 134, 397-397	2.2	3
16	A genome-scale screen for synthetic drivers of T cell proliferation.. <i>Nature</i> , 2022 , 603, 728-735	50.4	3
15	Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. <i>Lancet Haematology</i> , 2021 , 8, e891-e901	14.6	2
14	Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 269-290	5	2
13	New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 626-636	7.1	2
12	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
11	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018 , 132, 453-453	2.2	1
10	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018 , 132, 623-623	2.2	1
9	CART19 in Hodgkin lymphoma: are we driving the right model?. <i>Blood</i> , 2018 , 132, 982-983	2.2	1
8	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020 , 136, 46-49	2.2	
7	Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study. <i>American Journal of Hematology</i> , 2021 ,	7.1	
6	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018 , 132, 93-93	2.2	
5	A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. <i>Blood</i> , 2019 , 134, 1541-1541	2.2	
4	Microenvironment-related biomarkers and novel targets in Hodgkin lymphoma 2015 , 20-34		

- 3 Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis. *Blood*, **2016**, 128, 2949-2949 2.2
- 2 Expanding landscape for relapsed Hodgkin lymphoma. *Blood*, **2021**, 138, 421-422 2.2
- 1 New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond. *Expert Review of Hematology*, **2021**, 14, 741-750 2.8